EP1615614A4 - Vaccin polyvalent optimal contre le cancer - Google Patents

Vaccin polyvalent optimal contre le cancer

Info

Publication number
EP1615614A4
EP1615614A4 EP04759415A EP04759415A EP1615614A4 EP 1615614 A4 EP1615614 A4 EP 1615614A4 EP 04759415 A EP04759415 A EP 04759415A EP 04759415 A EP04759415 A EP 04759415A EP 1615614 A4 EP1615614 A4 EP 1615614A4
Authority
EP
European Patent Office
Prior art keywords
optimal
vaccine against
against cancer
versatile
versatile vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP04759415A
Other languages
German (de)
English (en)
Other versions
EP1615614A2 (fr
Inventor
Philip O Livingston
Govindaswami Ragupathi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of EP1615614A2 publication Critical patent/EP1615614A2/fr
Publication of EP1615614A4 publication Critical patent/EP1615614A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP04759415A 2003-04-09 2004-04-09 Vaccin polyvalent optimal contre le cancer Ceased EP1615614A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46162203P 2003-04-09 2003-04-09
PCT/US2004/011122 WO2004091507A2 (fr) 2003-04-09 2004-04-09 Vaccin polyvalent optimal contre le cancer

Publications (2)

Publication Number Publication Date
EP1615614A2 EP1615614A2 (fr) 2006-01-18
EP1615614A4 true EP1615614A4 (fr) 2007-08-22

Family

ID=33299843

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04759415A Ceased EP1615614A4 (fr) 2003-04-09 2004-04-09 Vaccin polyvalent optimal contre le cancer

Country Status (4)

Country Link
EP (1) EP1615614A4 (fr)
JP (1) JP2006522828A (fr)
CA (1) CA2521812A1 (fr)
WO (1) WO2004091507A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1458242A4 (fr) 2001-07-06 2006-06-07 Sloan Kettering Inst Cancer Vaccin conjugue polyvalent contre le cancer
US20060035267A1 (en) * 2003-04-09 2006-02-16 Livingston Philip O Optimal polyvalent vaccine for cancer
US8383118B2 (en) 2005-12-08 2013-02-26 Medarex, Inc. Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1
US9125848B2 (en) 2010-06-10 2015-09-08 The Cleveland Clinic Foundation Alpha lactalbumin immunization methods
CA2870537A1 (fr) * 2012-04-16 2013-10-24 The Cleveland Clinic Foundation Vaccin multivalent contre le cancer du sein
JP2015227292A (ja) * 2014-05-30 2015-12-17 国立大学法人高知大学 膵がん細胞浸潤転移抑制ワクチン
CN109154600A (zh) * 2016-06-16 2019-01-04 豪夫迈·罗氏有限公司 用于确定cdc诱导抗体的测定法和方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003003985A2 (fr) * 2001-07-06 2003-01-16 Sloan-Kettering Institute For Cancer Research Vaccin conjugue polyvalent contre le cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003003985A2 (fr) * 2001-07-06 2003-01-16 Sloan-Kettering Institute For Cancer Research Vaccin conjugue polyvalent contre le cancer

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
GILEWSKI T ET AL: "Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 98, no. 6, 13 March 2001 (2001-03-13), pages 3270 - 3275, XP002964246, ISSN: 0027-8424 *
KRUG ET AL: "Development of a tetravalent small cell lung cancer (SCLC) vaccine containing GM2, fucosyl GM1, Globo H, and polysialic acid", LUNG CANCER, vol. 41, 1 August 2003 (2003-08-01), pages S47, XP005875064 *
KRUG L.M. ET AL: "Vaccination of Small Cell Lung Cancer Patients with Polysialic Acid or N-Propionylated Polysialic Acid Conjugated to Keyhole Limpet Hemocyanin", CLINICAL CANCER RESEARCH, vol. 10, no. 3, 1 February 2004 (2004-02-01), pages 916 - 923 *
KRUG LEE M.: "Vaccine therapy for small cell lung cancer", SEMINARS IN ONCOLOGY, vol. 31, no. 1, 1 February 2004 (2004-02-01), pages 112 - 116, XP008098213 *
LIVINGSTON P.: "Current status of cancer vaccines against cell surface antigens on small cell lung cancer.", BIOTECNOLOGIA APLICADA, vol. 19, no. 3-4, 2002, pages 192 *
LIVINGSTON P.: "Immunization of mice with polysialic acid and N-propionylated polysialic acid-KLH conjugates plus QS-21 results in antibodies against human small cell lung cancer cells", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 42, March 2001 (2001-03-01), pages 288, XP008012617 *
PATEL JYOTI D ET AL: "TARGETING LETHAL MINIMAL RESIDUAL DISEASE IN SMALL CELL LUNG CANCER", SEMINARS IN ONCOLOGY, W.B. SAUNDERS,, US, vol. 30, no. 1, February 2003 (2003-02-01), pages 79 - 85, XP008077869, ISSN: 0093-7754 *
RAGUPATHI G ET AL: "Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 20, no. 7-8, 15 January 2002 (2002-01-15), pages 1030 - 1038, XP004332972, ISSN: 0264-410X *
RAGUPATHI G ET AL: "THE CASE FOR POLYVALENT CANCER VACCINES THAT INDUCE ANTIBODIES", EXPERT REVIEW OF VACCINES, FUTURE DRUGS, LONDON, GB, vol. 1, no. 2, August 2002 (2002-08-01), pages 193 - 206, XP008048224, ISSN: 1476-0584 *
ZHANG SHENGLE ET AL: "Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides", INTERNATIONAL JOURNAL OF CANCER, vol. 73, no. 1, 1997, pages 42 - 49, XP002431043, ISSN: 0020-7136 *

Also Published As

Publication number Publication date
WO2004091507A3 (fr) 2005-12-15
WO2004091507A2 (fr) 2004-10-28
EP1615614A2 (fr) 2006-01-18
CA2521812A1 (fr) 2004-10-28
JP2006522828A (ja) 2006-10-05

Similar Documents

Publication Publication Date Title
FR23C1005I1 (fr) Vaccins contre les flavivirus
MA28609B1 (fr) Vaccins
DK1959991T3 (da) Terapeutisk vaccine
NO20054608D0 (no) Influensavirusvaksine
EP1678292A4 (fr) Vaccins mva ameliores
EP1917040A4 (fr) Vaccin polyvalent
MA28885B1 (fr) vaccins
DK1968631T3 (da) Vaccine
DK2609947T3 (da) Plasterlignende infusionsapparat
IS8363A (is) Endurbætur á bólusetningum
DE602004017700D1 (de) Transmukosen verabreichung
IS8387A (is) Ónæmisvaldandi samsetningar
MA28639B1 (fr) Vaccins
EP1423141A4 (fr) Vaccin
IS7831A (is) Bóluefni
EP1660636A4 (fr) Vaccins anticancer
EP1667701A4 (fr) Vaccin antitumoral
GB0329146D0 (en) Vaccine
DK1597171T3 (da) Terapeutisk mikroskum
EP2061502A4 (fr) Vaccin
DE60328408D1 (de) Impfstoff
MA26270A1 (fr) Vaccin contre la variole
EP1615614A4 (fr) Vaccin polyvalent optimal contre le cancer
EP1807116A4 (fr) Vaccination antigrippale
EP2054081A4 (fr) Vaccin contre le virus jc

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

17P Request for examination filed

Effective date: 20051104

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/00 20060101ALI20051221BHEP

Ipc: G01N 33/543 20060101ALI20051221BHEP

Ipc: G01N 33/53 20060101AFI20051221BHEP

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20070724

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/68 20060101ALI20070713BHEP

Ipc: A61K 39/00 20060101ALI20070713BHEP

Ipc: G01N 33/543 20060101ALI20070713BHEP

Ipc: G01N 33/53 20060101ALI20070713BHEP

Ipc: G01N 33/574 20060101AFI20070713BHEP

17Q First examination report despatched

Effective date: 20071106

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20100311